Newsroom
Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
NodThera to Participate in Cantor Global Healthcare Conference
NLRP3 inhibitor reduces inflammatory biomarkers in high-risk patients
Healio